{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-008511","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2026-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.672695+00:00","generated_at":"2026-05-15T10:28:06.152687+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pulse Biosciences realigns to accelerate AFib catheter program after strong clinical data","bullets":["100% acute success at 6 months (75/75 patients); 96% durable PVI at 12 months (45/47).","Reducing headcount in sales/marketing; redirecting resources to cardiac catheter program and pivotal IDE study.","Streamlining soft-tissue ablation to focus on benign thyroid nodules and real-world data.","Late-breaking 12-month follow-up data to be presented at Heart Rhythm 2026 on April 25."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-008511","json":"https://secwatch.observer/filing/0001437749-26-008511.json","markdown":"https://secwatch.observer/filing/0001437749-26-008511.md","text":"https://secwatch.observer/filing/0001437749-26-008511.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926008511/0001437749-26-008511-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926008511/plse20260316c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T10:28:06.152687+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}